Senti Biosciences (SNTI) EBITDA (2021 - 2025)
Senti Biosciences' quarterly EBITDA came in at -$14.5 million in Q4 2025, down 2271.64% year-on-year from $666178.8 in Q4 2024, and up 20.19% quarter-over-quarter from -$18.1 million in Q3 2025.
Senti Biosciences has reported EBITDA for 5 years, with the latest figure at -$14.5 million in Q4 2025.
- For the quarter ending Q4 2025, EBITDA fell 2271.64% year-over-year to -$14.5 million; the trailing twelve-month figure through Dec 2025 stood at -$61.4 million (down 16.38% YoY), and the FY2025 full-year result was -$61.4 million, down 16.38% from the prior year.
- EBITDA for Q4 2025 stood at -$14.5 million, up from -$18.1 million in the prior quarter.
- The five-year high for EBITDA was -$1178.0 in Q1 2021, with the low at -$28.9 million in Q3 2024.
- Average EBITDA over 5 years is -$13.9 million, with a median of -$14.3 million recorded in 2025.
- Year-over-year, EBITDA tumbled 1002276.91% in 2022 and surged 96.74% in 2024.
- Tracing SNTI's EBITDA over 5 years: stood at -$10.9 million in 2021, then plunged by 66.99% to -$18.2 million in 2022, then retreated by 2.78% to -$18.7 million in 2023, then surged by 96.74% to -$610000.0 in 2024, then sank by 2271.64% to -$14.5 million in 2025.
- The last three EBITDA figures came in at -$14.5 million (Q4 2025), -$18.1 million (Q3 2025), and -$14.7 million (Q2 2025), per Business Quant data.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | EBITDA (Qtr) |
|---|---|---|---|---|---|
| 1 | Quantum Biopharma | 961,148.99 Bn | 961,148.98 Bn | - | -13.63 Mn |
| 2 | Alterity Therapeutics | 744,933.29 Bn | 744,933.26 Bn | - | - |
| 3 | Legend Biotech | 2,540.00 Bn | 2,539.71 Bn | 242.10 Mn | -19.70 Mn |
| 4 | Nanobiotix | 2,199.85 Bn | 2,199.78 Bn | - | - |
| 5 | Akari Therapeutics | 1,635.88 Bn | 1,635.88 Bn | - | -14.44 Mn |
| 6 | Vertex Pharmaceuticals | 111.32 Bn | 104.07 Bn | 2.59 Bn | 1.14 Bn |
| 7 | Evaxion A | 62.56 Bn | 62.54 Bn | - | -3.82 Mn |
| 8 | Regeneron Pharmaceuticals | 62.55 Bn | 53.79 Bn | 3.31 Bn | 661.60 Mn |
| 9 | Alnylam Pharmaceuticals | 39.57 Bn | 36.56 Bn | 959.66 Mn | 201.19 Mn |
| 10 | Senti Biosciences Holdings | 22.25 Mn | 22.25 Mn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | -14.47 Mn |
| Sep 30, 2025 | -18.13 Mn |
| Jun 30, 2025 | -14.73 Mn |
| Mar 31, 2025 | -14.11 Mn |
| Dec 31, 2024 | -610,000.00 |
| Sep 30, 2024 | -28.87 Mn |
| Jun 30, 2024 | -11.20 Mn |
| Mar 31, 2024 | -12.11 Mn |
| Dec 31, 2023 | -18.72 Mn |
| Sep 30, 2023 | -14.92 Mn |
| Jun 30, 2023 | -18.70 Mn |
| Mar 31, 2023 | -18.72 Mn |
| Dec 31, 2022 | -18.21 Mn |
| Sep 30, 2022 | -16.64 Mn |
| Jun 30, 2022 | -11.55 Mn |
| Mar 31, 2022 | -11.81 Mn |
| Dec 31, 2021 | -10.90 Mn |
| Sep 30, 2021 | -11.41 Mn |
| Jun 30, 2021 | -12.01 Mn |
| Mar 31, 2021 | -1,178.00 |